227. Osler disease Clinical trials / Disease details


Clinical trials : 54 Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-004179-11-IT
(EUCTR)
03/09/202117/08/2021Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telangiectasiaEffectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagictelangiectasia and symptomatic gastrointestinal bleeding, SAIPAN-trial: a multicentre,randomized, open-label, parallel-group, superiority trial. - SAIPAN study Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease(in specific patients with gastrointestinal bleeding and transfusion dependency)
MedDRA version: 21.0;Level: PT;Classification code 10019883;Term: Hereditary haemorrhagic telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: octreotide a azione pronta 0,1 mg
Product Code: [OCTREOTIDE ACETATO]
INN or Proposed INN: OCTREOTIDE ACETATO
RADBOUD UNIVERSITY MEDICAL CENTERNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
38Phase 3France;Denmark;Netherlands;Germany;United Kingdom;Italy
2ChiCTR2100043253
2021-02-172021-02-09The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab in the treatment of refractory epistaxis caused by HHTThe study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab in the treatment of refractory epistaxis caused by HHT hereditary hemorrhagic telangiectasiaTrial group:Bevacizumab;Shandong Provincial ENT HospitalNULLRecruiting1675BothTrial group:30;Phase 4China
3EUCTR2018-004179-11-FR
(EUCTR)
20/01/202126/11/2020The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial. - SAIPAN-trial Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Octreotide
INN or Proposed INN: OCTREOTIDE
RadboudumcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
38Phase 3France;Germany;Netherlands
4NCT04404881
(ClinicalTrials.gov)
November 23, 202022/5/2020Bevacizumab In Hereditary Hemorrhagic TelangiectasiaA Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: BevacizumabHanny Al-Samkari, MDNULLRecruiting18 YearsN/AAll20Phase 2United States
5NCT04646356
(ClinicalTrials.gov)
October 20, 202020/10/2020Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;Epistaxis NosebleedDrug: Tacrolimus capsule (low-dose)Unity Health TorontoUnited States Department of DefenseRecruiting18 YearsN/AAll30Phase 2Canada
6EUCTR2018-004179-11-DE
(EUCTR)
12/08/202012/03/2020The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding.Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and symptomatic gastrointestinal bleeding,the SAIPAN-trial: a multicenter, randomized, open-label, parallel-group,superiority trial. - SAIPAN-trial Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease (in specific patients with gastrointestinalbleedings);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Other descriptive name: OCTREOTIDE ACETATERadboudumcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
38Phase 3Italy;United Kingdom;Germany;Netherlands;France
7NCT04113187
(ClinicalTrials.gov)
June 23, 202027/9/2019Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia PatientsStudy of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia PatientsHereditary Hemorrhagic Telangiectasia;Osler Weber Rendu DiseaseDrug: Propranolol treatment;Drug: PlaceboUniversity Hospital, BordeauxAMRO-HHT-France - Association Maladie de Rendu-OslerActive, not recruiting18 YearsN/AAll15Phase 3France
8NCT03954782
(ClinicalTrials.gov)
June 22, 202015/5/2019Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II StudyTelangiectasia, Hereditary Hemorrhagic;Rendu Osler DiseaseDrug: Nintedanib 150 mg and 100 mg soft capsules;Drug: Oral treatment of placebo soft capsuleHospices Civils de LyonNULLRecruiting18 YearsN/AAll60Phase 2France
9EUCTR2019-003585-40-NL
(EUCTR)
17/12/201930/09/2019Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patientsAn uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia - Tacrolimus for bleeding in HHT patients Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by mucocutaneous telangiectasis. Telangiectasis predominantly observed in the nasal mucosa and gut, and are abnormal, thin walled blood vessel that can easily rupture leading to hemorrhage.
MedDRA version: 20.0;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Tacrolimus (Advagraf)
Product Name: Tacrolimus (Advagraf)
Product Code: EMEA/H/C/000712
St. Antonius HospitalNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
20 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noNetherlands
10EUCTR2019-002593-31-FR
(EUCTR)
05/11/201905/09/2019Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREEfficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseA national, randomized, multicenter phase II studyEPICURE Hereditary Hemorrhagic Telangiectasia
MedDRA version: 20.1;Level: LLT;Classification code 10019887;Term: Hereditary hemorrhagic telangiectasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: OFEV
Product Name: nintédanib
Other descriptive name: NINTEDANIB
Hospices Civils de LyonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2France
11NCT04139018
(ClinicalTrials.gov)
October 20, 201923/10/2019Timolol Gel for Epistaxis in Hereditary Hemorrhagic TelangiectasiaEfficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled TrialHereditary Hemorrhagic TelangiectasiaDrug: Timolol Gel;Drug: Placebo GelWashington University School of MedicineNULLRecruiting20 YearsN/AAll30Phase 2United States
12NCT03910244
(ClinicalTrials.gov)
October 17, 20198/4/2019Pomalidomide for the Treatment of Bleeding in HHTPomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic TelangiectasiaTelangiectasia, Hereditary HemorrhagicDrug: Pomalidomide Oral Product;Drug: Placebo oral capsuleThe Cleveland ClinicRTI InternationalRecruiting18 YearsN/AAll159Phase 2United States
13NCT03850730
(ClinicalTrials.gov)
September 201912/2/2019Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic TelangiectasiaAn Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: PazopanibCure HHTUniversity of North CarolinaNot yet recruiting18 Years75 YearsAll30Phase 1/Phase 2NULL
14NCT03850964
(ClinicalTrials.gov)
September 201912/2/2019Pazopanib Effects on Bleeding in Hereditary Hemorrhagic TelangiectasiaRandomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;AnemiaDrug: Pazopanib;Drug: Placebo oral capsuleCure HHTNULLNot yet recruiting18 Years75 YearsAll45Phase 2/Phase 3NULL
15EUCTR2018-004179-11-NL
(EUCTR)
03/06/201914/05/2019The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial. - SAIPAN-trial Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Octreotide
INN or Proposed INN: OCTREOTIDE
RadboudumcNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
38 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noNetherlands
16NCT03397004
(ClinicalTrials.gov)
September 12, 201821/11/2017Doxycycline for Hereditary Hemorrhagic TelangiectasiaDoxycycline Crossover Trial for Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic Telangiectasia (HHT)Drug: Doxycycline Hyclate;Drug: PlaceboUnity Health TorontoBarrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences CentreActive, not recruiting18 YearsN/AAll30Phase 2Canada
17NCT03981562
(ClinicalTrials.gov)
July 16, 201824/5/2019Vitamin D and Hereditary Haemorrhagic TelangiectasiaVitamin D Supplementation and Reduction of Severity and Frequency of Epistaxis in Hereditary Haemorrhagic TelangiectasiaHereditary Haemorrhagic TelangiectasiaDrug: Vit D;Drug: Placebo Oral TabletSt. Paul's Hospital, CanadaNULLRecruiting19 YearsN/AAll60Phase 2Canada
18NCT03572556
(ClinicalTrials.gov)
June 28, 20188/6/2018Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic TelangiectasiaBiological: Blood samples;Other: Epistaxis chartsCentre Hospitalier Universitaire DijonNULLCompleted18 YearsN/AAll60France
19EUCTR2017-003272-31-NL
(EUCTR)
18/05/201811/01/2018Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasiaEfficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patients Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease
MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850
MedDRA version: 20.0;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Sporanox
Product Name: Itraconazole
St. Antonius ZiekenhuisNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2Netherlands
20ChiCTR1900027420
2018-01-012019-11-12genetic screening for hereditary hemorrhagic telangiectasiaInvestigation and applyling on the genetic screening kit for hereditary hemorrhagic telangiectasia hereditary hemorrhagic telangiectasiaGold Standard:Clinical outcomes;Index test:To identified the pathogenic variant through genetic testing for the coding region of ENG, ACVRL1, SMAD4 and BMP9.;Beijing Institute of OtolaryngologyNULLRecruitingBothTarget condition:54;Difficult condition:0China
21NCT03227263
(ClinicalTrials.gov)
September 28, 201721/7/2017BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III StudyRendu Osler Disease;Telangiectasia, Hereditary HemorrhagicDrug: Bevacizumab;Drug: sodium chloride 0.9%Hospices Civils de LyonNULLCompleted18 YearsN/AAll24Phase 3France
22NCT02963129
(ClinicalTrials.gov)
June 20179/8/2016Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHTTreatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: Mupirocin;Other: PlaceboHospital Italiano de Buenos AiresNULLNot yet recruiting18 YearsN/ABoth40Phase 3Argentina
23EUCTR2017-001031-39-FR
(EUCTR)
19/05/201719/06/2020BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT)BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study. - BABH Hemorrhagic Hereditary Telangiectasia
MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: AVASTIN
Product Name: BEVACIZUMAB
INN or Proposed INN: BEVACIZUMAB
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
24Phase 3France
24EUCTR2016-003982-24-ES
(EUCTR)
16/03/201709/12/2016Study to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeksA phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks Hereditary hemorrhagic telangiectasia
MedDRA version: 19.0;Level: LLT;Classification code 10020023;Term: HHT;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Dicynone
INN or Proposed INN: Etamsylate
Other descriptive name: ETAMSYLATE
Asociación HHT EspañaNULLNot Recruiting Female: yes
Male: yes
12 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesSpain
25NCT02874326
(ClinicalTrials.gov)
October 201617/8/2016Octreotide in Patients With GI Bleeding Due to Rendu-Osler-WeberAn Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal BleedingHereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;AnemiaDrug: Octreotide LARRadboud UniversitySt. Antonius HospitalUnknown status18 YearsN/AAll15Phase 2Netherlands
26EUCTR2016-001340-19-NL
(EUCTR)
21/07/201611/07/2016The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease.An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Sandostatin LAR 20 mg
Product Name: Sandostatin LAR
Product Code: RVG 18236
Radboud University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands
27NCT02638012
(ClinicalTrials.gov)
December 201513/10/2015Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT);EpistaxisDrug: Floseal;Other: PackingSt. Michael's Hospital, TorontoThe Ottawa HospitalCompleted18 YearsN/AAll8N/ACanada
28NCT02484716
(ClinicalTrials.gov)
June 201517/6/2015Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus PlaceboTelangiectasia, Hereditary Hemorrhagic;Osler Rendu DiseaseDrug: Timolol nasal spray;Drug: Placebo nasal sprayHospices Civils de LyonNULLCompleted18 YearsN/AAll58Phase 2France
29EUCTR2015-000385-55-FR
(EUCTR)
12/05/201529/03/2017Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler.TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO Rendu-Osler disease
MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Timolol Alcon 0.5% collyre
Other descriptive name: TIMOLOL MALEATE
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France
30NCT02287558
(ClinicalTrials.gov)
January 27, 20156/11/2014Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I StudyA Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory AngiodysplasiaHereditary Hemorrhagic Telangiectasia;Idiopathic Vascular EctasiaDrug: PomalidomideThe Cleveland ClinicNULLCompleted18 YearsN/AAll9Phase 1United States
31NCT02157987
(ClinicalTrials.gov)
December 15, 20144/6/2014Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTreatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTelangiectasia, Hereditary HemorrhagicDrug: bevacuzimab sprayUniversity Hospital, CaenNULLRecruiting18 Years70 YearsAll30Phase 1/Phase 2France
32NCT02389959
(ClinicalTrials.gov)
August 4, 201411/3/2015Intranasal Bevacizumab for HHT-Related EpistaxisIntranasal Bevacizumab for HHT-Related EpistaxisHHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal BleedingDrug: Bevacizumab;Drug: Placebo (Saline)Stanford UniversityNULLCompleted18 YearsN/AAll40Phase 4United States
33NCT02106520
(ClinicalTrials.gov)
April 20141/4/2014Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: Bevacizumab;Drug: placeboHospices Civils de LyonNULLTerminated18 YearsN/ABoth80Phase 2/Phase 3France
34EUCTR2013-004204-19-FR
(EUCTR)
26/02/201416/06/2015Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-OslerEfficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORI Rendu-Osler disease
MedDRA version: 18.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Avastin
Product Name: Avastin
INN or Proposed INN: BEVACIZUMAB
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
France
35NCT01908543
(ClinicalTrials.gov)
July 201323/7/2013Iron Deficiency and Hereditary Haemorrhagic TelangiectasiaIron Deficiency and Hereditary Haemorrhagic TelangiectasiaHereditary Haemorrhagic TelangiectasiaDrug: Ferrous sulphate 200mg oral tabletImperial College LondonNULLTerminated18 Years80 YearsAll3N/AUnited Kingdom
36NCT01752049
(ClinicalTrials.gov)
May 201314/12/2012Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptTopical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptHereditary Hemorrhagic TelangiectasiaDrug: Topical timolol maleate;Drug: placebo saline dropsUnity Health TorontoUniversity of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)Completed18 YearsN/AAll5N/ACanada
37NCT01485224
(ClinicalTrials.gov)
November 201128/11/2011Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic TelangiectasiaEfficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: ThalidomideIRCCS Policlinico S. MatteoNULLCompleted18 YearsN/AAll31Phase 2Italy
38EUCTR2011-004096-36-IT
(EUCTR)
11/10/201119/03/2012Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaEfficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
MedDRA version: 14.1;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: THALIDOMIDE CELGENE*28CPS 50MG
INN or Proposed INN: THALIDOMIDE
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
31Phase 2Italy
39NCT01507480
(ClinicalTrials.gov)
October 20116/12/2011The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic TelangiectasiaThe ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.Rendu Osler Disease;Telangiectasia, Hereditary HemorrhagicDrug: BevacizumabHospices Civils de LyonNULLCompleted18 YearsN/AAll42Phase 1France
40NCT01408030
(ClinicalTrials.gov)
August 20111/8/2011North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)North American Study of Epistaxis in HHT (NOSE)Telangiectasia, Hereditary Hemorrhagic;EpistaxisDrug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic AcidJames GossageHHT Foundation InternationalCompleted18 YearsN/AAll123Phase 2United States
41NCT01406639
(ClinicalTrials.gov)
July 201129/7/2011Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT);NosebleedsDrug: RanibizumabUniversity of California, San DiegoGenentech, Inc.Withdrawn18 YearsN/ABoth0Phase 1United States
42NCT01314274
(ClinicalTrials.gov)
March 20119/3/2011Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic TelangiectasiaHHT;Morbus Osler;EpistaxisDrug: Bevacizumab;Drug: NaClMedical University of ViennaNULLCompleted18 Years80 YearsBoth15Phase 2Austria
43NCT01408732
(ClinicalTrials.gov)
February 20111/7/2011Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic TelangiectasiaOffice-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic TelangiectasiaEpistaxis;Hereditary Hemorrhagic TelangiectasiaDrug: Sclerotherapy;Other: Standard TreatmentUniversity of MinnesotaAmerican Rhinologic SocietyCompleted18 YearsN/AAll18Phase 1/Phase 2United States
44EUCTR2009-018049-19-AT
(EUCTR)
13/12/201023/11/2010A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHTA randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT epistaxisTrade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
INN or Proposed INN: BEVACIZUMAB
Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Other descriptive name: SODIUM CHLORIDE
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und OhrenkrankheitenNULLNot RecruitingFemale: yes
Male: yes
30Austria
45NCT01402531
(ClinicalTrials.gov)
July 22, 201019/7/2011Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: Submucosal BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll10Phase 2United States
46NCT01397695
(ClinicalTrials.gov)
June 200918/7/2011Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll20Phase 2United States
47EUCTR2008-006755-44-FR
(EUCTR)
15/01/200917/03/2009METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFOREMETAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE Maladie de Rendu-Osler
MedDRA version: 9.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease
Trade Name: AVASTIN
Product Name: AVASTIN
INN or Proposed INN: BEVACIZUMAB
Other descriptive name: SUB16402MIG
HOSPICES CIVILS DE LYONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2France
48EUCTR2010-020545-26-IT
(EUCTR)
09/12/200810/09/2010BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - NDBEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
MedDRA version: 9.1;Level: SOC;Classification code 10005329
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
49NCT00588146
(ClinicalTrials.gov)
January 200726/12/2007Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic TelangiectasiaPhase 2 Study of PEG-Intron in Hereditary Hemorrhagic TelangiectasiaAnemia;Liver Disease;HypoxemiaDrug: Pegylated Interferon Alpha2b;Other: Standard careMayo ClinicAugusta University;St. Michael's Hospital, Toronto;Schering-PloughTerminated18 Years70 YearsAll10Phase 2United States
50NCT00389935
(ClinicalTrials.gov)
October 200617/10/2006Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingArteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;MelenaDrug: ThalidomideNorthport Veterans Affairs Medical CenterGeorgia Regents University;University of Massachusetts, WorcesterCompleted18 YearsN/ABoth14Phase 2United States
51NCT00375622
(ClinicalTrials.gov)
February 200512/9/2006Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical TrialHereditary Hemorrhagic TelangiectasiaDrug: TamoxifenRabin Medical CenterNULLCompleted18 YearsN/ABoth60Phase 2Israel
52NCT01031992
(ClinicalTrials.gov)
March 200211/12/2009Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid.University Hospital, SaarlandPharmacia GmbH, Erlangen, Germany;Baxter Healthcare CorporationCompleted18 YearsN/ABoth23Phase 3Germany
53NCT00004654
(ClinicalTrials.gov)
January 199624/2/2000Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: soy protein isolateNational Center for Research Resources (NCRR)Yale UniversityCompleted15 YearsN/ABoth60Phase 3NULL
54NCT00004327
(ClinicalTrials.gov)
January 199518/10/1999Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile EctasiaHereditary Hemorrhagic Telangiectasia;EctasiaDrug: octreotideNational Center for Research Resources (NCRR)Yale UniversityCompletedN/AN/ABoth8Phase 2NULL